JAMA Neurology

• Errors in Abstract, Discussion, Table 1, Table 2, and Supplement 1

  The Original Investigation titled “Lecanemab Treatment in a Specialty Memory Clinic,” published online May 12, 2025, was corrected to fix errors in the Abstract and Discussion, add a footnote to Table 1, fix the formatting of a column in Table 2, and to update an eFigure in Supplement 1. The article was corrected online.

• JAMA Neurology

  Mission Statement: The mission of JAMA Neurology is to publish and disseminate scientific information primarily important for physicians caring for people with neurologic disorders and for those interested in the structure and function of the normal and diseased human nervous system. The specific aims are to (1) publish timely original research, including clinical trials that will directly improve clinical neurologic care and that will inform efforts to improve neurological health and promote health care equity; (2) report translational research that is pertinent to the understanding of neurologic disease; (3) address topics of practice, ethics, education, and public health that are a key part of modern medicine; and (4) provide a forum for discussion and publication of important topics including bias, racism, and diversity. This information will be published only after extensive review by scientific peers and journal editors so that clarity, rigor, originality, and precision are ensured.

• Risk of Parkinson Disease in Individuals With Autism Spectrum Disorder

  This cohort study of individuals in Sweden examines the association between autism spectrum disorder and future Parkinson disease risk.

• Targeting Vascular Risk Factors to Reduce Dementia Risk

• Antithrombotic Therapy After Burr Hole Evacuation of Chronic Subdural Hematoma

  This study investigates outcomes in patients undergoing surgery for chronic subdural hematoma comparing those receiving vs not receiving antithrombotic therapy.

• A Distinctive Inspiratory Noise in IgLON5-Antibody Disease

  This case series describes a distinctive inspiratory noise observed during sleep in patients with IgLON5-antibody disease.

• Prevalence of Epilepsy in Frontotemporal Dementia and Timing of Dementia Diagnosis

  This case-control study assesses the prevalence of epilepsy as a comorbidity of frontotemporal dementia (FTD) as well as the frequency of antiseizure medication purchases among patients with FTD compared with health controls and patients with Alzheimer disease.

• Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome

  This study attempts to identify prognostic factors at radiologically isolated syndrome diagnosis associated with the development of multiple sclerosis symptoms.

• Midlife and Late-Life Vascular Risk Factors and Incident Dementia

  This cohort study investigates what fraction of incident dementia is attributable to modifiable vascular risk factors.

• Residual Risk of Recurrent Stroke Despite Anticoagulation in Patients With Atrial Fibrillation

  This systematic review and meta-analysis determines the residual risk of recurrent stroke risk in patients with atrial fibrillation.

• Hemorrhage Into the Canal of Gratiolet

  This case report describes a unilateral basal ganglia hemorrhage passing through the anterior commissure within the canal of Gratiolet to the contralateral side.

• Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease

  This study compares individuals who have discrepant biological and clinical stages with those who have congruent stages in terms of copathologies, comorbidities, and demographics.

• Efficacy and Safety of Eptinezumab in Episodic Cluster Headache

  This randomized clinical trial investigates if eptinezumab is efficacious and well tolerated for the treatment of episodic cluster headache.

• Quantitative Muscle MR Outcomes in Duchenne Muscular Dystrophy

  This exploratory analysis of the EMBARK (A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec [SRP-9001] in Participants With Duchenne Muscular Dystrophy [DMD]) randomized clinical trial investigates how quantitative magnetic resonance measures can be used to evaluate the efficacy of delandistrogene moxeparvovec vs placebo for the treatment of patients with DMD.

• Rizatriptan vs Placebo for Attacks of Vestibular Migraine

  This randomized clinical trial examines the efficacy of rizatriptan for treating vestibular migraine attacks.

• Lecanemab Treatment in a Specialty Memory Clinic

  This study examines the feasibility and safety of treating patients in specialty memory clinics with lecanemab.

• Beyond the Cure

  This essay describes the author’s experiences treating patients.

• Opsoclonus-Myoclonus-Ataxia Syndrome in a Patient With Subacute Sclerosing Panencephalitis

  This case report describes jerky movements of all 4 limbs, recurrent falls, progressive cognitive impairment, and opsoclonus in a 4-year-old child.

• Functional Seizures—A Critical Comorbidity Overlooked in Epilepsy Research

  To the Editor We read with interest the article by Kwon et al, which offers valuable insights into the psychiatric burden associated with seizure disorders. However, it omitted functional seizures (FSs), also known as psychogenic nonepileptic seizures, from the range of comorbidities discussed. Given their prevalence and impact, this oversight warrants attention.

• Functional Seizures—A Critical Comorbidity Overlooked in Epilepsy Research—Reply

  In Reply We appreciate the thoughtful comments regarding the exclusion of functional seizures (FSs) as a comorbidity in our study. We recognize its significance as a comorbidity in epilepsy care and research, and we understand the need for greater awareness and methodological advancements to improve its documentation and representation, especially in population-based datasets. However, our decision to omit it from this systematic review was based on several methodological considerations. Our study specifically focused on population-based datasets with stringent inclusion criteria. Although FSs are an important comorbidity in epilepsy populations, large-scale epidemiological studies have inherent challenges in accurately capturing FS due to diagnostic and coding limitations. There are few validation studies assessing the accuracy of coding for FS in administrative and population-based datasets. The existing studies indicate a poor positive predictive value, which raises concerns about misclassification and diagnostic reliability within such datasets. Variations in how different electronic health record systems interpret and apply the F44.5 code can further contribute to inaccuracies in coding. Accurate coding of FSs often requires careful review of clinical documentation and consideration of presenting symptoms beyond just the International Classification of Diseases (ICD) code alone. Due to the overlap in symptoms between functional and epileptic seizures, misclassification can occur even with the use of specific ICD codes. Prior research has highlighted that when neurologists diagnose functional neurological disorders, including FSs, they often do not code for them separately. This underreporting further complicates efforts to reliably include FSs in population-level studies. Also, FSs have not been included in major national health surveys, further limiting their representation in large epidemiological datasets. The lack of standardized coding and inconsistent inclusion in national registries restricts the ability to assess its true burden in the general population. Moreover, although a prior heterogeneous meta-analysis has explored the dual diagnosis of epilepsy and FS, the 2 population-based studies included in that analysis focused on incidence, whereas our study was limited to prevalence studies. For these reasons, we excluded FSs from our study. However, we acknowledge its importance as a comorbidity in epilepsy studies and emphasize the need for further research to enhance its documentation and study in large datasets.

• Frailty and Implications for Multiple Sclerosis Management

  This Viewpoint discusses the unique needs of patients with multiple sclerosis and frailty and describes the gaps that should be addressed in frailty measurement and clinical management.

• Evolving Perspectives on α-Synuclein Testing

  This Viewpoint discusses evolving perspectives on α-synuclein testing.